Overview

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Status:
Withdrawn

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to look at a subset of plexiform neurofibromas and determine if the airway tumors are more sensitive to imatinib therapy. Funding Source - FDA OOPD

Phase:

Phase 2

Details

Lead Sponsor:

Indiana University

Collaborator:

Food and Drug Administration (FDA)

Treatments:

Imatinib Mesylate